INSIGHTS ON DRUG DEVELOPMENT

• Delivering Macromolecules: Challenges Associated With The Delivery Of Biologic Drugs

  Developers need to look beyond the formulation of a stable drug all the way to patient compliance. Numerous pitfalls exist along the journey to bring a biologic combination product to market. This integrated solutions program can help you simplify the journey.

• Materials Characterization In Pharma

  Materials science is now helping pharmaceutical companies to standardize and control areas such as drug form and manufacture to deliver new products more quickly and with greater quality.

• Zydis® Bio Technology, Grazax® & Grastek®: Revolutionizing Allergy Therapy

  ALK-Abelló is a global research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies. Before ALK-Abelló partnered with Catalent, all marketed allergen immunotherapies were delivered by injection, resulting in a limited patient population and reduced patient adherence. Catalent worked with the client to apply Zydis Fast Dissolve Technology to their therapy, bringing a vastly superior product to market.

• Viral Clearance: 7 Chromatography Column Considerations

  Viral clearance studies are a critical part of the production of biologics. Here are seven things to consider while performing your next chromatography viral clearance study.

• Developing A Scalable Process For Adenovirus Manufacturing

  To address the growing need for speed and efficiency in viral vector manufacturing, GE developed a process for adenovirus manufacturing that not only meets regulatory requirements but is also scalable.

• 6 Regulatory Changes Affecting Bioprocessing In China

  This article outlines six recent regulatory changes in China intended to protect patient safety as well as reduce regulatory burdens and minimize delays.

• Best Practices For A Successful Bioprocess Technology Transfer

  A well-executed bioprocess technology transfer (tech transfer) is critical to ensure smooth knowledge transfer and optimal process reproducibility. 

• Overcoming Bioavailability Challenges In Oral Formulation Development

  With nearly 90% of developmental pipeline drugs consisting of poorly soluble molecules, formulation experts must address this obstacle by applying approaches to improve an API’s pharmacokinetics. 

• Capture OTC Market Share For Geriatric And Pediatric Patients

  This webinar discusses how the unique properties of gelatin have been used to develop chewable softgel formulations for the pediatric and geriatric patient populations.